TY - JOUR
T1 - Daily use of consensus interferon
T2 - One-year treatment results for chronic hepatitis C patients relapsing or non-responding to previous interferon
AU - Karasu, Z.
AU - Gurakar, A.
AU - Jazzar, A.
AU - Wright, H.
PY - 2000/11/27
Y1 - 2000/11/27
N2 - Background/aim: The optimal dose, duration and frequency of interferon treatment for chronic hepatitis C is not clear. Preliminary hepatitis C virus kinetic studies have suggested that daily interferon is more advantageous than thrice in a week administration. Recently, a synthetic recombinant interferon, consensus interferon, has been approved for clinical application. There is no data available about daily use of consensus interferon. Methods: Our study protocol was designed to investigate the efficacy of long-term (12 month) daily consensus interferon therapy for chronic hepatitis C patients, who have either relapsed or not responded to previous interferon therapy. Eleven patients were included in the study. Results: Overall, eight (72%) patients became serum HCV-RNA negative. Of these, 60% (3/5) were among previous non-responders and 83% (5/6) were among previous relapsers. Conclusions: Our preliminary data suggests that daily use of consensus interferon provides encouraging results in relapsers and non-responders. However, further time is needed to evaluate the sustained response rate.
AB - Background/aim: The optimal dose, duration and frequency of interferon treatment for chronic hepatitis C is not clear. Preliminary hepatitis C virus kinetic studies have suggested that daily interferon is more advantageous than thrice in a week administration. Recently, a synthetic recombinant interferon, consensus interferon, has been approved for clinical application. There is no data available about daily use of consensus interferon. Methods: Our study protocol was designed to investigate the efficacy of long-term (12 month) daily consensus interferon therapy for chronic hepatitis C patients, who have either relapsed or not responded to previous interferon therapy. Eleven patients were included in the study. Results: Overall, eight (72%) patients became serum HCV-RNA negative. Of these, 60% (3/5) were among previous non-responders and 83% (5/6) were among previous relapsers. Conclusions: Our preliminary data suggests that daily use of consensus interferon provides encouraging results in relapsers and non-responders. However, further time is needed to evaluate the sustained response rate.
KW - Consensus interferon
KW - Hepatitis C
UR - http://www.scopus.com/inward/record.url?scp=0033732698&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033732698&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:0033732698
SN - 1300-4948
VL - 11
SP - 191
EP - 195
JO - Turkish Journal of Gastroenterology
JF - Turkish Journal of Gastroenterology
IS - 3
ER -